Labcorp reports Q2 sales of $3.73 billion, lifts full-year revenue outlook despite missing consensus

Labcorp announced second‑quarter revenue of $3.73 billion, up from $3.53 billion a year earlier, driven by strong performance across its core businesses.

The Diagnostics division grew 5.5% to $2.9 billion, while the Biopharma Laboratory Services segment rose 6.5% to $836.2 million, reflecting continued demand for specialty testing.

Revenue fell short of analysts' consensus estimate of $3.82 billion, prompting the stock to slip more than 2% in early trading after the results were released.

Despite the miss, Labcorp raised its full‑year 2026 revenue guidance to a range of $14.71 billion‑$14.82 billion, slightly above its prior outlook of $14.65 billion‑$14.80 billion.